84 related articles for article (PubMed ID: 20801048)
21. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.
Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H
J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150
[TBL] [Abstract][Full Text] [Related]
22. Potential serotonergic and noradrenergic involvement in the discriminative stimulus effects of the selective imidazoline I2-site ligand 2-BFI.
MacInnes N; Handley SL
Pharmacol Biochem Behav; 2003 May; 75(2):427-33. PubMed ID: 12873635
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .
Rondu F; Le Bihan G; Wang X; Lamouri A; Touboul E; Dive G; Bellahsene T; Pfeiffer B; Renard P; Guardiola-Lemaitre B; Manechez D; Penicaud L; Ktorza A; Godfroid JJ
J Med Chem; 1997 Nov; 40(23):3793-803. PubMed ID: 9371245
[TBL] [Abstract][Full Text] [Related]
24. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
[TBL] [Abstract][Full Text] [Related]
25. Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.
Berenguer I; El Aouad N; Andujar S; Romero V; Suvire F; Freret T; Bermejo A; Ivorra MD; Enriz RD; Boulouard M; Cabedo N; Cortes D
Bioorg Med Chem; 2009 Jul; 17(14):4968-80. PubMed ID: 19540762
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of new efaroxan derivatives for use in purification of imidazoline-binding sites.
Chan SL; Pallett AL; Clews J; Ramsden CA; Chapman JC; Kane C; Dunne MJ; Morgan NG
Eur J Pharmacol; 1998 Aug; 355(1):67-76. PubMed ID: 9754940
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of imidazoline I2 binding sites in pig brain.
Anderson NJ; Lupo PA; Nutt DJ; Hudson AL; Robinson ES
Eur J Pharmacol; 2005 Sep; 519(1-2):68-74. PubMed ID: 16109401
[TBL] [Abstract][Full Text] [Related]
29. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
30. Benzofuranyl-2-imidazoles as imidazoline I
Rodriguez-Arévalo S; Bagán A; Griñán-Ferré C; Vasilopoulou F; Pallàs M; Brocos-Mosquera I; Callado LF; Loza MI; Martínez AL; Brea J; Pérez B; Molins E; De Jonghe S; Daelemans D; Radan M; Djikic T; Nikolic K; Hernández-Hernández E; García-Fuster MJ; García-Sevilla JA; Escolano C
Eur J Med Chem; 2021 Oct; 222():113540. PubMed ID: 34118720
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationship of dopaminergic halogenated 1-benzyl-tetrahydroisoquinoline derivatives.
El Aouad N; Berenguer I; Romero V; Marín P; Serrano A; Andujar S; Suvire F; Bermejo A; Ivorra MD; Enriz RD; Cabedo N; Cortes D
Eur J Med Chem; 2009 Nov; 44(11):4616-21. PubMed ID: 19628309
[TBL] [Abstract][Full Text] [Related]
32. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
33. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of potent retinoid X receptor alpha agonists.
Haffner CD; Lenhard JM; Miller AB; McDougald DL; Dwornik K; Ittoop OR; Gampe RT; Xu HE; Blanchard S; Montana VG; Consler TG; Bledsoe RK; Ayscue A; Croom D
J Med Chem; 2004 Apr; 47(8):2010-29. PubMed ID: 15056000
[TBL] [Abstract][Full Text] [Related]
35. Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
Al-Fulaij MA; Ren Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2007 Apr; 321(1):298-307. PubMed ID: 17204745
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the effects of 2-BFI and tracizoline, two potent I
Hernández-Hernández E; García-Fuster MJ
Naunyn Schmiedebergs Arch Pharmacol; 2021 May; 394(5):989-996. PubMed ID: 33415506
[TBL] [Abstract][Full Text] [Related]
37. Reversible inhibition of intracellular calcium influx through NMDA receptors by imidazoline I(2) receptor antagonists.
Jiang SX; Zheng RY; Zeng JQ; Li XL; Han Z; Hou ST
Eur J Pharmacol; 2010 Mar; 629(1-3):12-9. PubMed ID: 19958763
[TBL] [Abstract][Full Text] [Related]
38. Novel 4-alkyl-1-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity.
Paluchowska MH; Mokrosz MJ; Charakchieva-Minol S; Duszyńska B; Kozioł A; Wesołowska A; Stachowicz K; Chojnacka-Wójcik E
Pol J Pharmacol; 2003; 55(4):543-52. PubMed ID: 14581712
[TBL] [Abstract][Full Text] [Related]
39. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
